Immunotherapy duo shows promise for chinese cancer patients

NCT ID NCT03195478

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 33 times

Summary

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients whose advanced solid tumors had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. While the treatment aims to control the disease, it is not a cure, and patients may need ongoing management.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution

Guangzhou, Guangdong, 510080, China
Local Institution

Zhengzhou, Henan, 450052, China
Local Institution - 0001

Beijing, Beijing Municipality, 100142, China
Local Institution - 0004

Tianjin, Tianjin Municipality, 300222, China
Local Institution - 0011

Harbin, Heilongjiang, 155040, China
Local Institution - 0012

Guangzhou, Guangdong, 510655, China
Local Institution - 0013

Hangzhou, Zhejiang, 310009, China
Local Institution - 0015

Beijing, Beijing Municipality, 100021, China
Local Institution - 0016

Shanghai, Shanghai Municipality, 200025, China
Local Institution - 0018

Chengdu, Sichuan, 610041, China
Local Institution - 0020

Xi'an, Shan1xi, 710061, China
Local Institution - 0021

Wuhan, Hubei, 430030, China

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR